MDCX Company Profile and Key Details

MDCX has shown weak momentum, losing -6.16% over the past week and -41.95% over the past quarter, though year-to-date performance is down -10.46%. Short-term trend indicators are bullishly aligned (SMA20 19.6%, SMA50 0.4%, SMA200 -43.72%). The stock’s 14-day RSI is 59.18 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.79% below its high and over 48.25% above its low. Average 10-day trading volume of 1.45 million shares is below the 3-month average of 1.98 million, indicating normal recent market interest.

Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) closed at $0.37 USD, losing -$0.02 (-5.31%) from the previous close of $0.39. The stock is currently mid-range between its 52-week high and low $0.25 and $3.12. With a market capitalization of about $8.09 million, Medicus Pharma Ltd. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.65). Key stats such as the average daily volume over the past year has been around 2.12 million shares, volume is running light vs its 52-week average. Headquartered in W. Conshohocken, None, Medicus Pharma Ltd. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raza Bokhari, the company employs approximately 16 people and listed since November 15, 2024. Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases.

Medicus Pharma Ltd. Common Stock has 18.72 million shares outstanding. The public float is 9.21 million shares, elevated short interest at 3.01% of float. This equals 345.96 thousand shares. The short ratio is 1.04 days. Institutional investors hold 4.67% of the float. Insiders own 12.48%.

Medicus Pharma Ltd. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 11.71% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $9.00. The high target offers 6823.08% upside. The low target suggests 2207.69% downside. The mean target is $25.62. This offers 6469.23% upside. Medicus Pharma Ltd. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 14, 2026, missed forecasts by 72.22%. The prior quarter beat by 72.22%. Over the last six quarters, Apple has recorded several small beats. These include 82.61% in May 12, 2025.

Medicus Pharma Ltd. Common Stock trades at a P/E ratio of -0.17, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.45 trading at moderately above to book value. The P/FCF stands at -0.36, also above market averages.

Our AI price prediction model suggests that Medicus Pharma Ltd. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.59%, with price expected at $0.39 by August 04, 2026, within a range of $0.34 to $0.45 3-Month Outlook: Projected rise of 101.19%, reaching $0.78 by October 19, 2026, with a range of $0.53 to $0.89. 1-Year Outlook: Projected loss of -63.89%, with price at $0.14 by July 21, 2027, within a range of $0.00 to $0.00.

Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) shares are down -10.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medicus Pharma Ltd. Common Stock trading at a premium to the broader market with a P/E of -0.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.94, suggesting 6332.81% upside. Our AI forecast model points to short-term strength (0.59% over two weeks), a medium-term rise (101.19% over three months), and a longer-term loss (-63.89% over one year), with expected trading ranges indicating moderate volatility.